Compare Johnson & Johnson (JNJ) vs Starbucks Corp (SBUX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Johnson & Johnson vs Starbucks Corp — how do they compare? Johnson & Johnson trades at $260.33 (market cap $618.09B), while Starbucks Corp trades at $92.28 (market cap $106.26B). The key difference: Johnson & Johnson is far larger — about 5.8× Starbucks Corp's market cap, and Starbucks Corp pays the higher dividend (2.7%). Which is the better fit depends on your goals — on Pluang, investors hold Johnson & Johnson for 129 Days and Starbucks Corp for 190 Days on average.
| JNJ | SBUX | |
|---|---|---|
Market Cap | $618.09B | $106.26B |
Volume | 6,050,983 | 30,248,434 |
Sector | Health | Consumer Cyclical |
52-Week High | $278.43 | $108.55 |
52-Week Low | $186.00 | $78.46 |
Typical Hold Time | 129 Days | 190 Days |
Enterprise Value | $646.37B | $125.08B |
Dividend Yield | 2.09% | 2.7% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Johnson & Johnson (JNJ) trades at $259.62, up 0.45% with a bearish technical signal despite recent earnings beats. The stock shows strong fundamentals with 21.48% net margin and 25.74% ROE, though valuation ratios appear elevated with P/E at 29.75. Recent news highlights growth in the Innovative Medicine segment and positive analyst coverage with 52.5% buy ratings.
JNJ offers stable dividend income and pharmaceutical innovation upside, but faces patent cliff risks and increasing debt-to-asset ratio (24.06% in 2025). Analyst consensus target of $286.53 suggests 10% upside potential, though technical resistance at $260 may limit near-term gains.
Starbucks (SBUX) trades at $91.66, down 2.05% amid a bearish technical outlook with support at $89 and resistance at $92. The company reported mixed quarterly results with Q2 2026 EPS beating expectations at $0.85 vs. $0.66, but Q4 2025 missed at $0.56. Recent news highlights store closures and restructuring charges of approximately $300 million as part of a strategic turnaround. Revenue growth remains modest at $37.18B for 2025, with net income margin at 5.17%.
The stock presents a cautious opportunity with analyst consensus price target of $115.50 implying 26% upside, though high P/E of 53.88 raises valuation concerns. Key risks include execution of store optimization, labor relations, and geopolitical tensions in China. Institutional sentiment is divided with 47% buy ratings, but technical indicators signal near-term pressure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Johnson & Johnson
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →About Starbucks Corp
Starbucks Corporation retails, roasts, and provides its own brand of specialty coffee. The Company operates retail locations worldwide and sells whole bean coffees through its sales group, direct response business, supermarkets, and on the world wide web. Starbucks also produces and sells bottled coffee drinks and a line of ice creams.
Read more on SBUX →
